Dr. Neelapu on Primary Results of the ZUMA-1 Trial in NHL
Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.
Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma during the AACR Annual Meeting.
A total of 101 patients were enrolled in the study throughout 22 different sites. The primary analysis showed the overall response rate (ORR) was 82% and the complete response (CR) rate was 54%.
At the median follow-up of 8.7 months, 44% of patients had ongoing response, with 39% showing ongoing complete remissions, Neelapu explains.
This data compares favorably to historical data, Neelapu says. In a similar refractory patient population, the OR rate with existing therapies is 26% and the CR rate is only 8%. The median survival for current therapies is 6.5 months, where in this study, at 8.7 months, the majority of patients were still alive.
<<<
